A Phase 3 interventional study of Faster-acting insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 152 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-12.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one has the largest enrollment, is one of 5 that started in 2016, is one of 24 in phase 3, and was the 58th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Defymed · Sites in France
Ages 18+
By country, each count listing its studies:
Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 3 · Phase 3 26 · Phase 4 24
First in 1989; this study’s year is marked. 5 started in 2016.
This study's enrollment of 1,108 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 87 interventional studies. Of the 81 that completed or were terminated, 21 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 87 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 4th largest by enrollment of the 149 interventional ones that give a count, is one of 4 that started in 2016, is one of 54 in phase 3, and was the 184th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
2 of the studies testing Insulin Aspart in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia, Europe and North America. The purpose is to confirm efficacy in terms of glycaemic control of treatment with mealtime faster-acting insulin aspart in combination with insulin degludec in adults with Type 1 Diabetes Mellitus.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 1,108 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - Male or female, age greater than or equal to 18 years ( for Japan and Taiwan: age greater than or equal to 20 years) at the time of signing - Type 1 Diabetes Mellitus (based on clinical judgement and/or supported by laboratory analysis as per local guidelines) 12 months or more prior to screening - Currently treated with a basal-bolus insulin regimen for at least 12 months prior to screening (Visit 1) - Currently treated with a basal insulin analogue for at least 4 months prior to screening (Visit 1) - 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory - less than or equal to 35.0 kg/m\^2 Exclusion Criteria: - Within the past 180 days any of the following: myocardial infarction, stroke or hospitalization for unstable angina and/or - Subjects presently classified as being in (NYHA) Class IV Currently planned coronary, carotid or peripheral artery revascularisation - Diabetic ketoacidosis requiring hospitalisation within the last 180 days prior to screening (Visit 1) - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of three months before screening (Visit 1)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faster-acting insulin aspart · Drug: insulin degludec
Drug: insulin aspart · Drug: insulin degludec
Drug: Faster-acting insulin aspart · Drug: insulin degludec
Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
Change From Baseline in HbA1c 26 Weeks After Randomisation
Change from baseline (week 0) in HbA1c was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.
Time frame: Week 0, week 26
Change From Baseline in 1-hour Post Prandial Glucose (PPG) Increment 26 Weeks After Randomisation (Meal Test)
The 1-hour PPG increment was analysed based on the laboratory-measured values in the meal test, and was derived using the 1-hour PPG measurement minus the pre-prandial plasma glucose (PG). The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Change From Baseline in 1,5-anhydroglucitol 26 Weeks After Randomisation
The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Change From Baseline in Fasting Plasma Glucose (FPG) 26 Weeks After Randomisation
The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0%) 26 Weeks After Randomisation
The percentage of subjects who achieved the HbA1c target of \<7.0% 26 weeks after randomisation. Subjects without an HbA1c measurement at week 26 were treated as non-responders.
Time frame: 26 weeks after randomisation
Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia) 26 Weeks After Randomisation
The percentage of subjects who achieved the HbA1c target of \<7.0% without severe hypoglycaemia 26 weeks after randomisation. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an HbA1c measurement at week 26 were treated as non-responders.
Time frame: 26 weeks after randomisation
Percentage of Subjects Reaching HbA1c Targets (HbA1c < 7.0% Without Severe Hypoglycaemia and Minimal Weight Gain [<3.0%]) 26 Weeks After Randomisation
The percentage of subjects who achieved the HbA1c target of \<7.0% without severe hypoglycaemia and with minimal weight gain (defined as less than a 3% increase) 26 weeks after randomisation. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an HbA1c measurement at week 26 or without body weight measurement at week 26 were treated as non-responders.
Time frame: 26 weeks after randomisation
Change From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG 26 Weeks After Randomisation
Laboratory measured PG from the meal test was analysed for 30, 60, 120, 180, and 240 minutes PPG separately. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Change From Baseline in 30- Min, 1- Hour, 2- Hour, 3- Hour and 4- Hour PPG Increment 26 Weeks After Randomisation
Laboratory measured PG from the meal test was analysed for 30, 60, 120, 180, and 240 minutes PPG separately. The corresponding PPG increments were derived separately using each PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Change From Baseline in 7-9-7-point Self-measured Plasma Glucose (SMPG) 26 Weeks After Randomisation: Mean of the 7-9-7-point Profile
The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. The mean of the 7-9-7-point profile was defined as the area under the curve profile divided by the measurement time, and was calculated using the linear trapezoidal technique. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG (Mean, Breakfast, Lunch, Main Evening Meal)
The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. Results were derived from the three profiles: post-breakfast, post-lunch, post-main evening meal. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: PPG Increment (Mean, Breakfast, Lunch, Main Evening Meal)
The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. PPG increment for each meal (breakfast, lunch, main evening meal) was derived from the 7-point and 9-point profile as the difference between PPG values and the PG value before the meal in each separate profile. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Fluctuation in 7-9-7-point Profile
The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. Fluctuation in SMPG profile was the average absolute difference from the mean of the SMPG profile. Change from baseline is represented as ratio to baseline value. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 26
Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Change in the Nocturnal Self-measured Plasma Glucose Measurements
The subject was instructed to perform 7-9-7 SMPG point profile on 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast,60 minutes after the start of breakfast,before lunch,60 minutes after the start of lunch, before main evening meal,60 minutes after the start of main evening meal,and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on following day. Change from baseline in nocturnal PG values (nocturnal increments) was assessed by considering differences between PG values available at bedtime, at 4 a.m and the before breakfast value the following day: (04:00 PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 04:00 PG value). Results are based on the last in-trial value (the last available measurement in the in-trial period).
Time frame: Week 0, week 26
Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L
Percentage of subjects achieving an overall mean 1-hour PPG ≤7.8 mmol/L \[140 mg/dL\] 26 weeks after randomisation. Subjects without an overall mean 1-hour PPG at week 26 were treated as non-responders.
Time frame: 26 weeks after randomisation
Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L Without Severe Hypoglycaemia
Percentage of subjects achieving an overall mean 1-hour PPG ≤7.8 mmol/L \[140 mg/dL\] 26 weeks after randomisation without severe hypoglycaemia. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an overall mean 1-hour PPG at week 26 were treated as non-responders.
Time frame: 26 weeks after randomisation
Percentage of Subjects Reaching PPG Target (Overall Mean of Daily PPG Measurements in SMPG) 26 Weeks After Randomisation: Overall PPG (1 Hour) ≤7.8 mmol/L and HbA1c <7.0% and Minimal Weight Gain (<3.0%) Without Severe Hypoglycaemia
The percentage of subjects who achieved overall mean 1 hour PPG ≤7.8 mmol/L \[140 mg/dL\], had HbA1c \< 7.0% and had minimal weight gain (increase in body weight from baseline \<3.0%) 26 weeks after randomisation, and without severe hypoglycaemic episodes. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an overall mean 1-hour PPG or an HbA1c value or a body weight at week 26 were treated as non-responders.
Time frame: 26 weeks after randomisation
Change From Baseline in Lipids-lipoproteins Profile 26 Weeks After Randomisation (Total Cholesterol, High Density Lipoproteins [HDL] Cholesterol, Low Density Lipoproteins [LDL] Cholesterol)
Change from baseline in HDL cholesterol, LDL cholesterol and total cholesterol 26 weeks after randomization are represented as ratio to baseline values. The results are based on the last in-trial value (the last available measurement in the in-trial period).
Time frame: Week 0, week 26
Insulin Dose (Basal Insulin Dose, Total and Individual Meal Insulin Dose)
The insulin doses were summarised descriptively at week 0 and week 26 both by meal type and as total daily dose (total daily and separately for each mealtime dose). Week 26 results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Number of Treatment Emergent Adverse Events During 26 Weeks After Randomisation
A treatment emergent adverse event (TEAE) was defined as an event that had an onset date on or after the first day of exposure to randomised treatment, and no later than seven days after the last day of randomised treatment.
Time frame: Week 0 to week 26 (+7 days)
Number of Treatment-emergent Injection Site Reactions During the 26 Weeks After Randomisation
A treatment emergent event was defined as an event that had an onset date on or after the first day of exposure to randomised treatment, and no later than seven days after the last day of randomised treatment.
Time frame: Week 0 to week 26 (+7 days)
Number of Hypoglycaemic Episodes Classified Both According to the American Diabetes Association (ADA) Definition and Novo Nordisk (NN) Definition During 26 Weeks After Randomisation: Overall
ADA classification includes following criteria: Severe,Documented symptomatic,Asymptomatic,Probable symptomatic,Pseudo-hypoglycaemia. NN Classification: * Severe:same as per ADA classification * Symptomatic blood glucose (BG) confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed:PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic:severe according to ADA classification or BG confirmed by PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * BG confirmed:PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed:severe according to ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes. Treatment emergent episode: an event that has onset up to 1 day after last day of randomised treatment and excluding events occurring in run-in period.
Time frame: Week 0 to week 26 (+1 day)
Number of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: Daytime and Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)
ADA classification includes following criteria: Severe, Documented symptomatic, Asymptomatic, Probable symptomatic, Pseudo-hypoglycaemia. NN Classification: * Severe: same as per ADA classification * Symptomatic BG confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed: PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/Lwith symptoms consistent with hypoglycaemia * BG confirmed: PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05:59 both inclusive.
Time frame: Week 0 to week 26 (+1 day)
Number of Hypoglycaemic Episodes Classified Both According to the ADA Definition and Novo Nordisk Definition During 26 Weeks After Randomisation: From Start of Meal Until 1,2, 4 Hours and From 2 Hours (Exclusive) to 4 Hours (Inclusive) After Start of Meal
ADA classification includes following criteria: Severe, Documented symptomatic, Asymptomatic, Probable symptomatic, Pseudo-hypoglycaemia. NN Classification: * Severe: same as per ADA classification * Symptomatic BG confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed: PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/Lwith symptoms consistent with hypoglycaemia * BG confirmed: PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes related to meals.
Time frame: Week 0 to week 26 (+1 day)
Change From Baseline 26 Weeks After Randomisation in Clinical Evaluations (Physical Examination)
The physical examination parameters included head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system; gastrointestinal system including mouth; musculoskeletal system; central and peripheral nervous system; and skin. The examinations were measured as 'normal', 'abnormal, not clinically significant' (Abn, NCS) or 'abnormal, clinically significant' (Abn, CS). Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' physical examinations at week 0 and week 26. Week 26 results are based on the last on-treatment value (last value), which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Blood Pressure 26 Weeks After Randomisation
Change from baseline in systolic blood pressure and diastolic blood pressure 26 weeks after randomisation. Results are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Pulse 26 Weeks After Randomisation
Results are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Clinical Evaluation (Electrocardiogram) 26 Weeks After Randomisation
The electrocardiogram was interpreted by the investigator into following categories: Normal; Abn, NCS; Abnormal, CS. Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' physical examinations at week 0 and week 26. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Clinical Evaluation (Fundoscopy/Fundus Photography) 26 Weeks After Randomisation
The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abn, NCS; Abnormal, CS. Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at week 0 and week 26. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Erythrocytes 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Haematocrit 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Haemoglobin 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Leukocytes 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Thrombocytes 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Alanine Aminotransferase 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Albumin 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Alkaline Phosphatase 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Aspartate Aminotransferase 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Total Bilirubin 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Potassium 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Creatinine 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Total Protein 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Urinary Albumin-to-creatinine Ratio 26 Weeks After Randomisation
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Urinalysis (Ketones) 26 Weeks After Randomisation
Presence of ketone in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with ketone values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Urinalysis (Protein) 26 Weeks After Randomisation
Presence of protein in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with protein values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Urinalysis (Erythrocytes) 26 Weeks After Randomisation
Presence of erythrocytes in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with erythrocytes values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Anti-insulin Aspart (Specific and Cross-reacting With Human Insulin) Antibody Development 26 Weeks After Randomisation
Insulin aspart antibody titres (antibodies specific for insulin aspart and those cross-reacting with human insulin) measured at baseline and at 26 weeks. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period. Anti-insulin aspart antibody was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T).
Time frame: Week 0, week 26
Change From Baseline in Body Weight 26 Weeks After Randomisation
The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
Change From Baseline in Body Mass Index 26 Weeks After Randomisation
The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 26
The trial was conducted at 146 sites in 12 countries(number of sites indicates those that both screened and randomised subjects, unless otherwise noted)-Austria(4);Bulgaria(8); Canada(6); Germany(7); India(16); Israel(6); Italy(4); Japan(24); Russian Federation(10); Serbia(3); Taiwan(3); United States(55 sites screened/52 sites randomised subjects)
| Milestone | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Started | 342 | 341 | 342 |
| Exposed | 342 | 341 | 342 |
| Completed | 338 | 334 | 335 |
| Not completed | 4 | 7 | 7 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 6 | 4 |
| Withdrew: Unclassified | 0 | 0 | 1 |
Change from baseline (week 0) in HbA1c was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.
| percentage of HbA1c | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in HbA1c 26 Weeks After Randomisation | -0.12 ± 0.64 | 0.005 ± 0.64 | -0.09 ± 0.65 |
The 1-hour PPG increment was analysed based on the laboratory-measured values in the meal test, and was derived using the 1-hour PPG measurement minus the pre-prandial plasma glucose (PG). The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in 1-hour Post Prandial Glucose (PPG) Increment 26 Weeks After Randomisation (Meal Test) | -1.13 ± 4.04 | 1.04 ± 3.53 | -0.15 ± 3.78 |
The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| ug/mL | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in 1,5-anhydroglucitol 26 Weeks After Randomisation | 0.22 ± 2.23 | -0.15 ± 2.10 | 0.22 ± 2.25 |
The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) 26 Weeks After Randomisation | 0.17 ± 2.94 | 0.44 ± 3.29 | 0.64 ± 3.35 |
The percentage of subjects who achieved the HbA1c target of \<7.0% 26 weeks after randomisation. Subjects without an HbA1c measurement at week 26 were treated as non-responders.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Yes | 28.7 | 28.2 | 32.7 |
| No | 71.3 | 71.8 | 67.3 |
The percentage of subjects who achieved the HbA1c target of \<7.0% without severe hypoglycaemia 26 weeks after randomisation. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an HbA1c measurement at week 26 were treated as non-responders.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Yes | 25.7 | 26.4 | 30.4 |
| No | 74.3 | 73.6 | 69.6 |
The percentage of subjects who achieved the HbA1c target of \<7.0% without severe hypoglycaemia and with minimal weight gain (defined as less than a 3% increase) 26 weeks after randomisation. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an HbA1c measurement at week 26 or without body weight measurement at week 26 were treated as non-responders.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Yes | 16.4 | 17.9 | 19.3 |
| No | 83.6 | 82.1 | 80.7 |
Laboratory measured PG from the meal test was analysed for 30, 60, 120, 180, and 240 minutes PPG separately. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change in PPG at 30 min | -0.47 ± 3.58 | 1.31 ± 3.52 | 0.21 ± 3.78 |
| Change in PPG at 1 hour | -1.05 ± 4.56 | 1.39 ± 4.44 | 0.20 ± 4.52 |
| Change in PPG at 2 hours | -0.41 ± 5.17 | 0.80 ± 5.38 | 0.33 ± 5.51 |
| Change in PPG at 3 hours | -0.12 ± 5.20 | 0.93 ± 5.06 | 0.51 ± 5.33 |
| Change in PPG at 4 hours | 0.005 ± 4.64 | 0.83 ± 4.59 | 0.53 ± 4.60 |
Laboratory measured PG from the meal test was analysed for 30, 60, 120, 180, and 240 minutes PPG separately. The corresponding PPG increments were derived separately using each PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change in PPG increment at 30 min | -0.55 ± 2.55 | 0.94 ± 2.47 | -0.14 ± 2.63 |
| Change in PPG increment at 1 hour | -1.13 ± 4.04 | 1.04 ± 3.53 | -0.15 ± 3.78 |
| Change in PPG increment at 2 hours | -0.47 ± 4.74 | 0.42 ± 5.01 | -0.01 ± 5.15 |
| Change in PPG increment at 3 hours | -0.20 ± 4.89 | 0.55 ± 4.95 | 0.11 ± 5.32 |
| Change in PPG increment at 4 hours | -0.10 ± 4.47 | 0.45 ± 4.44 | 0.16 ± 4.63 |
The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. The mean of the 7-9-7-point profile was defined as the area under the curve profile divided by the measurement time, and was calculated using the linear trapezoidal technique. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in 7-9-7-point Self-measured Plasma Glucose (SMPG) 26 Weeks After Randomisation: Mean of the 7-9-7-point Profile | -0.304 ± 1.928 | -0.231 ± 1.846 | -0.309 ± 2.060 |
The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. Results were derived from the three profiles: post-breakfast, post-lunch, post-main evening meal. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change in PPG breakfast | -0.83 ± 3.34 | -0.03 ± 3.30 | -0.31 ± 3.18 |
| Change in PPG lunch | -0.59 ± 3.04 | 0.06 ± 2.98 | -0.33 ± 3.38 |
| Change in PPG main evening meal | -0.53 ± 3.55 | -0.01 ± 3.56 | -0.14 ± 3.22 |
| Change in PPG all meals | -0.65 ± 2.26 | -0.004 ± 2.19 | -0.25 ± 2.33 |
The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. PPG increment for each meal (breakfast, lunch, main evening meal) was derived from the 7-point and 9-point profile as the difference between PPG values and the PG value before the meal in each separate profile. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change in PPG increment breakfast | -1.14 ± 3.64 | 0.06 ± 3.51 | -0.30 ± 3.16 |
| Change in PPG increment lunch | -0.67 ± 3.20 | -0.08 ± 3.10 | -0.004 ± 3.31 |
| Change in PPG increment main evening meal | -0.29 ± 3.70 | 0.34 ± 3.54 | 0.26 ± 3.49 |
| Change in PPG increment all meals | -0.72 ± 2.06 | 0.08 ± 1.98 | -0.02 ± 2.01 |
The subject was instructed to perform a 7-9-7 SMPG point profile on the 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast, 60 minutes after the start of breakfast, before lunch, 60 minutes after the start of lunch, before main evening meal, 60 minutes after the start of main evening meal, and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on the following day. Fluctuation in SMPG profile was the average absolute difference from the mean of the SMPG profile. Change from baseline is represented as ratio to baseline value. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| ratio | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in 7-9-7-point SMPG 26 Weeks After Randomisation: Fluctuation in 7-9-7-point Profile | 0.876 ± 47.490 | 0.875 ± 40.293 | 0.890 ± 41.978 |
The subject was instructed to perform 7-9-7 SMPG point profile on 3 consecutive days just before selected visit. 7-point profile (day 3 and day 1 before selected visit): before breakfast,60 minutes after the start of breakfast,before lunch,60 minutes after the start of lunch, before main evening meal,60 minutes after the start of main evening meal,and at bedtime. 9-point profile (day 2 before selected visit) included all timepoints of 7-points profile with addition of SMPG measurement at 4 a.m. and before breakfast on following day. Change from baseline in nocturnal PG values (nocturnal increments) was assessed by considering differences between PG values available at bedtime, at 4 a.m and the before breakfast value the following day: (04:00 PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 04:00 PG value). Results are based on the last in-trial value (the last available measurement in the in-trial period).
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change in nocturnal increment-bedtime to 04:00 | 0.14 ± 5.66 | 0.19 ± 6.41 | 0.45 ± 5.55 |
| Change in nocturnal increment-bedtime to breakfast | 0.86 ± 6.21 | 0.93 ± 6.24 | 0.33 ± 5.71 |
| Change in nocturnal increment-04:00 to breakfast | 0.78 ± 4.95 | 1.01 ± 4.12 | -0.02 ± 4.17 |
Percentage of subjects achieving an overall mean 1-hour PPG ≤7.8 mmol/L \[140 mg/dL\] 26 weeks after randomisation. Subjects without an overall mean 1-hour PPG at week 26 were treated as non-responders.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Yes | 27.8 | 19.9 | 21.6 |
| No | 72.2 | 80.1 | 78.4 |
Percentage of subjects achieving an overall mean 1-hour PPG ≤7.8 mmol/L \[140 mg/dL\] 26 weeks after randomisation without severe hypoglycaemia. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an overall mean 1-hour PPG at week 26 were treated as non-responders.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Yes | 24.6 | 18.8 | 20.5 |
| No | 75.4 | 81.2 | 79.5 |
The percentage of subjects who achieved overall mean 1 hour PPG ≤7.8 mmol/L \[140 mg/dL\], had HbA1c \< 7.0% and had minimal weight gain (increase in body weight from baseline \<3.0%) 26 weeks after randomisation, and without severe hypoglycaemic episodes. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. Subjects without an overall mean 1-hour PPG or an HbA1c value or a body weight at week 26 were treated as non-responders.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Yes | 7.6 | 4.7 | 8.2 |
| No | 92.4 | 95.3 | 91.8 |
Change from baseline in HDL cholesterol, LDL cholesterol and total cholesterol 26 weeks after randomization are represented as ratio to baseline values. The results are based on the last in-trial value (the last available measurement in the in-trial period).
| ratio | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| HDL cholesterol | 0.981 ± 16.200 | 0.998 ± 17.283 | 0.999 ± 33.056 |
| LDL cholesterol | 1.025 ± 20.067 | 1.053 ± 22.465 | 1.062 ± 215.570 |
| Total cholesterol | 1.002 ± 14.561 | 1.030 ± 15.789 | 1.020 ± 15.891 |
The insulin doses were summarised descriptively at week 0 and week 26 both by meal type and as total daily dose (total daily and separately for each mealtime dose). Week 26 results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Units | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Daily bolus insulin dose: week 0 | 25.5 ± 15.4 | 25.4 ± 14.3 | 26.6 ± 14.8 |
| Daily bolus insulin dose: Last on-treatment value | 31.1 ± 19.4 | 30.5 ± 18.9 | 33.5 ± 22.5 |
| Daily basal insulin dose: week 0 | 25.3 ± 14.5 | 26.7 ± 15.6 | 26.2 ± 15.0 |
| Daily basal insulin dose: Last on-treatment value | 26.7 ± 16.6 | 27.3 ± 16.8 | 27.2 ± 17.3 |
| Total daily insulin dose: week 0 | 50.8 ± 26.1 | 52.2 ± 25.2 | 53.1 ± 25.9 |
| Total daily insulin dose: Last on-treatment value | 57.7 ± 31.4 | 57.8 ± 30.2 | 60.4 ± 34.0 |
| Daily breakfast bolus insulin dose: Last value | 8.8 ± 6.2 | 8.6 ± 6.0 | 9.5 ± 7.7 |
| Daily lunch bolus insulin dose: Last value | 10.5 ± 7.0 | 10.3 ± 6.9 | 11.2 ± 7.6 |
| Daily main evening meal bolus insulin: Last value | 11.9 ± 7.7 | 11.6 ± 7.4 | 12.7 ± 9.1 |
| Daily other bolus insulin dose: Last value | 4.7 ± 5.1 | 4.3 ± 3.5 | 4.2 ± 3.3 |
A treatment emergent adverse event (TEAE) was defined as an event that had an onset date on or after the first day of exposure to randomised treatment, and no later than seven days after the last day of randomised treatment.
| events | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Number of Treatment Emergent Adverse Events During 26 Weeks After Randomisation | 649 | 656 | 627 |
A treatment emergent event was defined as an event that had an onset date on or after the first day of exposure to randomised treatment, and no later than seven days after the last day of randomised treatment.
| Injection site reactions | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Number of Treatment-emergent Injection Site Reactions During the 26 Weeks After Randomisation | 9 | 12 | 10 |
ADA classification includes following criteria: Severe,Documented symptomatic,Asymptomatic,Probable symptomatic,Pseudo-hypoglycaemia. NN Classification: * Severe:same as per ADA classification * Symptomatic blood glucose (BG) confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed:PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic:severe according to ADA classification or BG confirmed by PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * BG confirmed:PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed:severe according to ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes. Treatment emergent episode: an event that has onset up to 1 day after last day of randomised treatment and excluding events occurring in run-in period.
| hypoglycaemic episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Number of Hypoglycaemic Episodes Classified Both According to the American Diabetes Association (ADA) Definition and Novo Nordisk (NN) Definition During 26 Weeks After Randomisation: Overall | 15760 | 16579 | 16520 |
ADA classification includes following criteria: Severe, Documented symptomatic, Asymptomatic, Probable symptomatic, Pseudo-hypoglycaemia. NN Classification: * Severe: same as per ADA classification * Symptomatic BG confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed: PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/Lwith symptoms consistent with hypoglycaemia * BG confirmed: PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05:59 both inclusive.
| hypoglycaemic episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Daytime hypoglycaemic episodes | 14570 | 15379 | 15257 |
| Nocturnal hypoglycaemic episodes | 1190 | 1200 | 1263 |
ADA classification includes following criteria: Severe, Documented symptomatic, Asymptomatic, Probable symptomatic, Pseudo-hypoglycaemia. NN Classification: * Severe: same as per ADA classification * Symptomatic BG confirmed: PG\<3.1 mmol/L with symptoms consistent with hypoglycaemia * Asymptomatic BG confirmed: PG\<3.1 mmol/L without symptoms consistent with hypoglycaemia * Severe or BG confirmed symptomatic: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/Lwith symptoms consistent with hypoglycaemia * BG confirmed: PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Severe or BG confirmed: severe according to the ADA classification or BG confirmed by PG\<3.1 mmol/L with or without symptoms consistent with hypoglycaemia * Unclassifiable Results represent total number of hypoglycaemic episodes related to meals.
| hypoglycaemic episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Within 1 hour after meal | 624 | 614 | 459 |
| Within 2 hours after meal | 1314 | 1470 | 1224 |
| Within 4 hours after meal | 3920 | 4794 | 4129 |
| Between 1 (exclusive) to 2 hours (inclusive) | 690 | 856 | 765 |
| Between 2 (exclusive) to 3 hours (inclusive) | 1236 | 1634 | 1302 |
| Between 2 (exclusive) to 4 hours (inclusive) | 2606 | 3324 | 2905 |
| Between 3 (exclusive) to 4 hours (inclusive) hours | 1370 | 1690 | 1603 |
The physical examination parameters included head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system; gastrointestinal system including mouth; musculoskeletal system; central and peripheral nervous system; and skin. The examinations were measured as 'normal', 'abnormal, not clinically significant' (Abn, NCS) or 'abnormal, clinically significant' (Abn, CS). Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' physical examinations at week 0 and week 26. Week 26 results are based on the last on-treatment value (last value), which included the last available measurement in the on-treatment period.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Cardiovascular system - Week 0: Normal | 97.4 | 98.8 | 97.7 |
| Cardiovascular system - Week 0: Abn, NCS | 2.6 | 0.9 | 2.0 |
| Cardiovascular system - Week 0: Abn, CS | 0.0 | 0.3 | 0.3 |
| Cardiovascular system - Last value: Normal | 97.4 | 98.8 | 97.9 |
| Cardiovascular system - Last value: Abn, NCS | 2.6 | 0.9 | 1.8 |
| Cardiovascular system - Last value: Abn, CS | 0.0 | 0.3 | 0.3 |
| Nervous system - Week 0: Normal | 83.9 | 86.8 | 86.3 |
| Nervous system - Week 0: Abn, NCS | 15.5 | 12.9 | 13.2 |
| Nervous system - Week 0: Abn, CS | 0.6 | 0.3 | 0.6 |
| Nervous system - Last value: Normal | 83.8 | 87.1 | 86.8 |
| Nervous system - Last value: Abn, NCS | 15.6 | 12.9 | 12.4 |
| Nervous system - Last value: Abn, CS | 0.6 | 0.0 | 0.9 |
| Gastrointestinal system-week 0: Normal | 99.7 | 98.8 | 98.2 |
| Gastrointestinal system-week 0: Abn, NCS | 0.3 | 0.9 | 0.9 |
| Gastrointestinal system-week 0: Abn, CS | 0.0 | 0.3 | 0.9 |
| Gastrointestinal system-Last value: Normal | 99.1 | 97.9 | 98.5 |
| Gastrointestinal system-Last value: Abn, NCS | 0.9 | 1.2 | 0.6 |
| Gastrointestinal system-Last value: Abn, CS | 0.0 | 0.9 | 0.9 |
| Head,ears,eyes,nose,throat,neck:week 0-Normal | 95.0 | 95.6 | 93.3 |
| Head,ear,eye,nose,throat,neck-week 0:Abn,NCS | 4.1 | 3.8 | 5.8 |
| Head,ears,eyes,nose,throat,neck-week 0:Abn,CS | 0.9 | 0.6 | 0.9 |
| Head,ears,eyes,nose,throat,neck-Last value:Normal | 95.3 | 92.9 | 94.1 |
| Head,ear,eye,nose,throat,neck-Last value:Abn,NCS | 3.8 | 6.2 | 4.4 |
| Head,ear,eye,nose,throat,neck-Last value:Abn,CS | 0.9 | 0.9 | 1.5 |
| Musculoskeletal system-week 0: Normal | 95.9 | 97.1 | 96.2 |
| Musculoskeletal system-week 0: Abn, NCS | 4.1 | 2.9 | 3.5 |
| Musculoskeletal system-week 0: Abn, CS | 0.0 | 0.0 | 0.3 |
| Musculoskeletal system-Last value: Normal | 96.8 | 97.4 | 95.3 |
| Musculoskeletal system-Last value: Abn, NCS | 3.2 | 2.6 | 3.8 |
| Musculoskeletal system-Last value: Abn, CS | 0.0 | 0.0 | 0.9 |
| Respiratory system-week 0: Normal | 99.4 | 99.4 | 99.1 |
| Respiratory system-week 0: Abn, NCS | 0.6 | 0.3 | 0.6 |
| Respiratory system-week 0: Abn, CS | 0.0 | 0.3 | 0.3 |
| Respiratory system-Last value: Normal | 99.7 | 99.4 | 99.4 |
| Respiratory system-Last value: Abn, NCS | 0.3 | 0.3 | 0.3 |
| Respiratory system-Last value: Abn, CS | 0.0 | 0.3 | 0.3 |
| Skin-week 0: Normal | 91.5 | 89.7 | 91.5 |
| Skin-week 0: Abn, NCS | 7.3 | 8.8 | 7.9 |
| Skin-week 0: Abn, CS | 1.2 | 1.5 | 0.6 |
| Skin-Last value: Normal | 91.5 | 91.5 | 92.4 |
| Skin-Last value: Abn, NCS | 7.6 | 6.2 | 6.5 |
| Skin-Last value: Abn, CS | 0.9 | 2.4 | 1.2 |
Change from baseline in systolic blood pressure and diastolic blood pressure 26 weeks after randomisation. Results are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| mmHg | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Diastolic blood pressure | 0.5 ± 8.3 | 0.2 ± 7.8 | 0.8 ± 7.9 |
| Systolic blood pressure | 0.6 ± 12.5 | 1.4 ± 10.8 | 0.8 ± 12.9 |
Results are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| beats/minute | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Pulse 26 Weeks After Randomisation | 0.0 ± 8.8 | -0.7 ± 9.3 | 0.7 ± 8.3 |
The electrocardiogram was interpreted by the investigator into following categories: Normal; Abn, NCS; Abnormal, CS. Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' physical examinations at week 0 and week 26. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Week 0: Normal | 80.7 | 81.8 | 84.2 |
| Week 0: Abn, NCS | 19.3 | 17.6 | 15.8 |
| Week 0: Abn, CS | 0.0 | 0.6 | 0.0 |
| Last on-treatment value: Normal | 80.8 | 84.0 | 82.3 |
| Last on-treatment value: Abn, NCS | 19.2 | 15.1 | 17.1 |
| Last on-treatment value: Abn, CS | 0.0 | 0.9 | 0.6 |
The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abn, NCS; Abnormal, CS. Reported results are percentage of subjects with 'normal', 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at week 0 and week 26. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Left eye-Week 0: Normal | 65.8 | 68.0 | 69.3 |
| Left eye-Week 0: Abn, NCS | 26.9 | 23.5 | 23.4 |
| Left eye-Week 0: Abn, CS | 7.3 | 8.5 | 7.3 |
| Left eye-Last on-treatment value: Normal | 62.5 | 69.4 | 69.3 |
| Left eye-Last on-treatment value: Abn, NCS | 29.7 | 21.0 | 21.1 |
| Left eye-Last on-treatment value: Abn, CS | 7.8 | 9.6 | 9.6 |
| Right eye-Week 0: Normal | 65.2 | 68.9 | 67.0 |
| Right eye-Week 0: Abn, NCS | 27.8 | 22.3 | 25.4 |
| Right eye-Week 0: Abn, CS | 7.0 | 8.8 | 7.6 |
| Right eye-Last on-treatment value: Normal | 64.0 | 67.9 | 68.7 |
| Right eye-Last on-treatment value: Abn, NCS | 29.1 | 22.5 | 22.6 |
| Right eye-Last on-treatment value: Abn, CS | 6.9 | 9.6 | 8.7 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| number of erythrocytes 10^12/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Erythrocytes 26 Weeks After Randomisation | -0.01 ± 0.24 | -0.03 ± 0.26 | -0.02 ± 0.26 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| percentage of red blood cells in blood | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Haematocrit 26 Weeks After Randomisation | -0.48 ± 2.58 | -0.52 ± 2.41 | -0.57 ± 2.45 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Haemoglobin 26 Weeks After Randomisation | -0.04 ± 0.51 | -0.04 ± 0.46 | -0.05 ± 0.50 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| Number of leukocytes 10^9/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Leukocytes 26 Weeks After Randomisation | -0.17 ± 1.63 | -0.03 ± 1.52 | -0.01 ± 1.46 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| Number of thrombocytes 10^9/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Thrombocytes 26 Weeks After Randomisation | -0.7 ± 40.0 | -2.0 ± 36.3 | -1.8 ± 33.7 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| U/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Alanine Aminotransferase 26 Weeks After Randomisation | 1.3 ± 10.1 | 0.9 ± 9.0 | 0.6 ± 11.6 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| g/dL | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Albumin 26 Weeks After Randomisation | -0.02 ± 0.25 | -0.05 ± 0.25 | -0.03 ± 0.25 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| U/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Alkaline Phosphatase 26 Weeks After Randomisation | 2.1 ± 18.9 | 1.4 ± 12.3 | -0.2 ± 14.4 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| U/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Aspartate Aminotransferase 26 Weeks After Randomisation | -0.0 ± 9.5 | -0.1 ± 9.4 | -0.3 ± 13.3 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| umol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Total Bilirubin 26 Weeks After Randomisation | -0.1 ± 3.3 | -0.2 ± 3.9 | -0.2 ± 3.3 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Potassium 26 Weeks After Randomisation | 0.01 ± 0.43 | 0.04 ± 0.42 | 0.04 ± 0.43 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| umol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Creatinine 26 Weeks After Randomisation | 2.0 ± 8.8 | 1.8 ± 7.5 | 1.8 ± 15.6 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| g/dL | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Total Protein 26 Weeks After Randomisation | 0.03 ± 0.40 | 0.02 ± 0.37 | -0.02 ± 0.36 |
Week 26 data are based on the last on-treatment value, which contains the last available measurement in the on-treatment period.
| mg/mmol | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Urinary Albumin-to-creatinine Ratio 26 Weeks After Randomisation | 0.636 ± 7.361 | -0.379 ± 11.095 | 0.656 ± 12.739 |
Presence of ketone in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with ketone values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Week 0: Negative | 96.2 | 97.1 | 92.7 |
| Week 0: Positive | 0.0 | 0.0 | 0.0 |
| Week 0: Trace | 2.0 | 1.8 | 5.3 |
| Week 0: 1+ | 1.8 | 1.2 | 1.8 |
| Week 0: 2+ | 0.0 | 0.0 | 0.3 |
| Week 0: 3+ | 0.0 | 0.0 | 0.0 |
| Last on-treatment value: Negative | 92.3 | 89.7 | 90.0 |
| Last on-treatment value:Positive | 0.0 | 0.0 | 0.0 |
| Last on-treatment value: Trace | 5.0 | 6.5 | 6.5 |
| Last on-treatment value:1+ | 2.1 | 3.2 | 2.9 |
| Last on-treatment value: 2+ | 0.6 | 0.6 | 0.6 |
| Last on-treatment value: 3+ | 0.0 | 0.0 | 0.0 |
Presence of protein in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with protein values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Week 0: Negative | 82.2 | 79.5 | 80.4 |
| Week 0: Positive | 0.0 | 0.0 | 0.0 |
| Week 0: Trace | 12.0 | 14.4 | 13.5 |
| Week 0: 1+ | 4.4 | 4.1 | 3.5 |
| Week 0: 2+ | 1.2 | 1.2 | 2.0 |
| Week 0: 3+ | 0.3 | 0.9 | 0.6 |
| Last on-treatment value: Negative | 83.5 | 82.6 | 78.8 |
| Last on-treatment value:Positive | 0.0 | 0.0 | 0.0 |
| Last on-treatment value: Trace | 8.6 | 10.9 | 12.4 |
| Last on-treatment value:1+ | 5.9 | 4.7 | 6.5 |
| Last on-treatment value: 2+ | 1.5 | 1.2 | 2.1 |
| Last on-treatment value: 3+ | 0.6 | 0.6 | 0.3 |
Presence of erythrocytes in urine was assessed by urine dipstick and categorised as: Negative, Positive, Trace, 1+, 2+, 3+. Change from baseline is represented in terms of percentage of patients with erythrocytes values at week 0 and week 26 (last on-treatment value). Last on-treatment value contains the last available measurement in the on-treatment period.
| percentage of subjects | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Week 0: Negative | 95.3 | 93.3 | 93.3 |
| Week 0: Positive | 0.0 | 0.0 | 0.0 |
| Week 0: Trace | 1.8 | 2.3 | 3.2 |
| Week 0: 1+ | 0.9 | 1.5 | 2.0 |
| Week 0: 2+ | 1.2 | 0.9 | 0.6 |
| Week 0: 3+ | 0.9 | 2.1 | 0.9 |
| Last on-treatment value: Negative | 93.5 | 91.7 | 91.8 |
| Last on-treatment value:Positive | 0.0 | 0.0 | 0.0 |
| Last on-treatment value: Trace | 2.7 | 3.8 | 2.6 |
| Last on-treatment value:1+ | 1.5 | 0.9 | 2.1 |
| Last on-treatment value: 2+ | 0.6 | 2.1 | 1.8 |
| Last on-treatment value: 3+ | 1.8 | 1.5 | 1.8 |
Insulin aspart antibody titres (antibodies specific for insulin aspart and those cross-reacting with human insulin) measured at baseline and at 26 weeks. Week 26 data are based on the last on-treatment value which contains the last available measurement in the on-treatment period. Anti-insulin aspart antibody was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T).
| % B/T | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Anti-insulin aspart specific antibodies | 0.033 ± 0.777 | -0.027 ± 1.077 | -0.013 ± 1.568 |
| Cross-reacting to human insulin | -0.972 ± 6.028 | -1.799 ± 6.812 | -1.427 ± 5.527 |
The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| kg | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Body Weight 26 Weeks After Randomisation | 1.43 ± 2.66 | 1.14 ± 2.95 | 1.24 ± 2.60 |
The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| kg/m^2 | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change From Baseline in Body Mass Index 26 Weeks After Randomisation | 0.49 ± 0.91 | 0.39 ± 1.02 | 0.43 ± 0.89 |
Collected over Week 0 to week 26 (+7 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Faster Aspart (Meal) | 0/342 (0%) | 20/342 (5.8%) | 154/342 (45%) |
| Faster Aspart (Post) | 0/341 (0%) | 17/341 (5%) | 152/341 (44.6%) |
| NovoRapid (Meal) | 0/342 (0%) | 17/342 (5%) | 161/342 (47.1%) |
| Event | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 8/342 | 3/341 | 6/342 |
| Hypoglycaemic unconsciousnessNervous system disorders | 2/342 | 3/341 | 2/342 |
| PolyneuropathyNervous system disorders | 0/342 | 2/341 | 0/342 |
| Hypoglycaemic seizureNervous system disorders | 2/342 | 1/341 | 0/342 |
| Wrong drug administeredInjury, poisoning and procedural complications | 0/342 | 0/341 | 2/342 |
| BursitisMusculoskeletal and connective tissue disorders | 0/342 | 1/341 | 0/342 |
| CellulitisInfections and infestations | 0/342 | 1/341 | 0/342 |
| Cerebrovascular accidentNervous system disorders | 0/342 | 1/341 | 0/342 |
| Chest painGeneral disorders | 0/342 | 1/341 | 0/342 |
| Diabetic metabolic decompensationMetabolism and nutrition disorders | 1/342 | 1/341 | 1/342 |
| Event | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 73/342 | 70/341 | 80/342 |
| Blood glucose decreasedInvestigations | 58/342 | 67/341 | 68/342 |
| Upper respiratory tract infectionInfections and infestations | 30/342 | 26/341 | 27/342 |
| InfluenzaInfections and infestations | 21/342 | 14/341 | 10/342 |
Full analysis set (FAS) included all randomised subjects.
| Age, Continuous(years) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| Mean | 41.48 ± 14.42 | 41.02 ± 14.59 | 40.77 ± 14.22 | 41.09 ± 14.40 |
| Sex: Female, Male(Participants) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| Female | 158 | 155 | 163 | 476 |
| Male | 184 | 186 | 179 | 549 |
| Ethnicity (NIH/OMB)(Participants) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 8 | 12 | 33 |
| Not Hispanic or Latino | 329 | 333 | 330 | 992 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 116 | 131 | 137 | 384 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 4 | 6 | 16 |
| White | 219 | 206 | 198 | 623 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Glycosylated hemoglobin (HbA1c)(percentage of HbA1c) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| Mean | 7.46 ± 0.68 | 7.40 ± 0.60 | 7.41 ± 0.79 | 7.42 ± 0.70 |
Showing the first 100 of 152 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Ran from May 2016 to primary completion in Jul 2017, 14 months.
Results were first posted in Aug 2018, 1 year after primary completion.
Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 14 months is below that.
Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Aspart